Alkem Laboratories Limited Stock Price Today (NSE: ALKEM)

Alkem Laboratories Limited

₹5264.00+₹14.50 (+0.28%)
Market Open

Fundamental Score

...

Alkem Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Alkem Laboratories Limited share price today is ₹5264.00, up +0.28% on NSE/BSE as of 9 October 2026. Alkem Laboratories Limited (ALKEM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹62.93K (Cr). The 52-week high for ALKEM share price is ₹5933.50 and the 52-week low is ₹5051.00. At a P/E ratio of 29.17x, ALKEM is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 17.84% and a debt-to-equity ratio of 0.12.

Alkem Laboratories Limited Share Price Chart — NSE/BSE Historical Performance

Alkem Laboratories Limited share price chart: -7.46% return over the past month. 52-week high ₹5933.50, 52-week low ₹5051.00.

Alkem Laboratories Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
₹5407.00₹5407.00₹5237.50₹5249.502.81L (Cr)
₹5297.00₹5404.50₹5292.00₹5350.502.05L (Cr)
₹5223.50₹5292.00₹5165.00₹5292.0063.67K (Cr)
₹5210.00₹5235.00₹5136.00₹5192.501.03L (Cr)
₹5150.00₹5220.00₹5110.00₹5220.002.91L (Cr)
₹5249.50₹5276.50₹5135.00₹5163.501.47L (Cr)
₹5166.50₹5306.50₹5152.00₹5250.002.44L (Cr)
₹5254.00₹5273.50₹5131.00₹5175.001.02L (Cr)
₹5322.50₹5325.00₹5237.00₹5274.0028.74K (Cr)
₹5372.00₹5447.00₹5261.50₹5326.001.65L (Cr)

Alkem Laboratories Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
₹5150.00₹5407.00₹5110.00₹5249.50+1.93%
₹5329.50₹5466.50₹5051.00₹5163.50-3.11%
₹5774.50₹5774.50₹5175.00₹5329.50-7.71%
₹5594.00₹5882.50₹5487.00₹5751.50+2.82%
₹5443.50₹5608.00₹5162.50₹5570.00+2.32%
₹5382.00₹5789.00₹5313.00₹5498.00+2.16%
₹5320.50₹5735.00₹5075.00₹5400.00+1.49%
₹5415.00₹5665.00₹5111.50₹5299.00-2.14%
₹5616.00₹5915.00₹5307.71₹5639.50+0.42%
₹5477.00₹5933.50₹5384.00₹5677.50+3.66%
₹5712.00₹5736.00₹5405.00₹5506.50-3.60%
₹5519.50₹5868.00₹5499.00₹5685.00+3.00%

Returns & Performance

Good

Return on Equity (ROE)

17.84%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

20.33%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

19.00%

Average operating profit margin over 5 years

Dividend Yield

0.80%

Annual dividend as % of current share price

Alkem Laboratories Limited Valuation Check

Good

Price to Earnings (P/E)

29.17x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

51.20%

% shares held by company founders/management

Good

FII Holding

10.42%

% shares held by foreign institutional investors

Excellent

DII Holding

22.64%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-21.72%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

10.95%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

15.30%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

6.44%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

6.44%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.12x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

18.86x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

6.49K (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Alkem Laboratories Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ALKEM across key market metrics for learning purposes.

Positive Indicators

11 factors identified

Strong Return on Equity (17.84%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (20.33%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (19.00%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Consistent Growth Track Record (15.30% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Conservative Debt Levels (D/E: 0.12)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (18.86x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 2.55)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹6493.50 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (51.20%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Strong Institutional Confidence (FII+DII: 33.06%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

Profit Decline Concern (-21.72%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Alkem Laboratories Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Alkem Laboratories Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
54/100
₹5264
₹62931.12
29.2
Average
17.84%
Good
20.33%
Excellent
0.1
Excellent
6.44%
Good
15.30%
Excellent
0.80%
66.4/100
₹1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
₹9468
₹250888.75
85.9
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
₹4940
₹167182.32
78.9
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
₹1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
₹1372
₹110828.94
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
₹1941
₹104867.93
95.8
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
₹1683
₹96839.82
26.3
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
₹2101
₹96054.51
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
₹1145
₹95565.75
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
₹2294
₹94729.81
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Alkem Laboratories Limited PE Ratio History

Historical price-to-earnings ratio for ALKEM — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 2025₹181.11₹5506.5030.4x
FY 2024₹150.19₹5633.9037.5x
FY 2023₹82.31₹5202.6063.2x
FY 2022₹137.63₹3004.7021.8x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Alkem Laboratories Limited Dividend History

Annual cash dividends paid by ALKEM — dividend yield 0.80%

Financial YearDividends Paid (₹ Cr)
FY 2025₹504.62 Cr
FY 2024₹540.49 Cr
FY 2023₹529.52 Cr
FY 2022₹421.91 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Alkem Laboratories Limited Quarterly Performance

Latest quarterly metrics for ALKEM — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

10.95%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-21.72%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

15.30%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

6.44%

Compounded annual net profit growth over 5 years

Alkem Laboratories Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ALKEM — calculated from daily price history

54RSI 14
Neutral — RSI 54

Momentum is balanced — neither overbought nor oversold.

SMA 50
₹5396
▼ Price below SMA 50 — Short-term bearish
SMA 200
₹5485
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
143K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Alkem Laboratories Limited Financial Statements

Annual income statement, balance sheet and cash flow for Alkem Laboratories Limited (ALKEM) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Alkem Laboratories Limited

Loading latest quarterly results...

About ALKEM (Alkem Laboratories Limited)

Alkem Laboratories Ltd is a global pharmaceutical powerhouse, emerging from India as a dynamic force in the healthcare landscape. With a foundation built on rigorous research and d...evelopment, Alkem meticulously crafts and distributes a diverse portfolio of pharmaceutical solutions. Their commitment extends from the creation of complex formulations to the manufacture of essential medicines, all adhering to the highest international quality standards. Alkem's dedication to innovation drives them to constantly explore novel therapeutic avenues, solidifying their position as a trusted partner for healthcare providers and patients across the globe. The company has a clear vision to address unmet medical needs with an emphasis on providing accessible, affordable, and effective treatments that improve lives. The company’s reach extends across multiple continents, fostering a robust network of manufacturing facilities, research centers, and distribution channels. Alkem distinguishes itself through a vertically integrated business model, enabling greater control over the entire product lifecycle, from raw material sourcing to finished dosage forms. This approach ensures consistent quality and cost-effectiveness, giving the company a competitive edge in the global pharmaceutical market. Furthermore, Alkem’s unwavering commitment to regulatory compliance and ethical practices has earned them the respect of healthcare authorities worldwide. Their ability to navigate complex regulatory landscapes facilitates the swift introduction of innovative products into new markets, making them a preferred partner for healthcare organizations. Beyond pharmaceuticals, Alkem actively explores related healthcare domains. They are expanding their portfolio to encompass a broader range of products, focusing on preventative healthcare and overall well-being. This strategic diversification reflects Alkem's commitment to becoming a holistic healthcare provider, addressing evolving patient needs. Alkem's focus also incorporates environmental responsibility, implementing sustainable manufacturing processes and striving to minimize its environmental footprint. The company’s dedication to sustainability demonstrates its long-term commitment to responsible business practices and a healthier future for all. This forward-thinking approach positions Alkem for continued growth and success in the rapidly evolving healthcare industry.

Company Details

Symbol:ALKEM
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Basudeo Narian Singh
Executive Chairman
Mr. Sandeep Derjit Singh
MD & Executive Director
Mr. Mritunjay Kumar Singh
Executive Director

ALKEM Share Price: Frequently Asked Questions

What is the current share price of Alkem Laboratories Limited?

Alkem Laboratories Limited (ALKEM) trades at ₹5264.00 on NSE and BSE. Market cap ₹62.93K (Cr). Educational data only.

What is the P/E ratio of Alkem Laboratories Limited?

Alkem Laboratories Limited has a P/E of 29.17x vs industry average 34.89x.

What is the Bull Run score for Alkem Laboratories Limited?

Alkem Laboratories Limited has a Bull Run score of 54/100 based on 25+ financial parameters.

Does Alkem Laboratories Limited pay dividends?

Alkem Laboratories Limited has a dividend yield of 0.80%. Past dividends don't guarantee future payments.

What is the ROE of Alkem Laboratories Limited?

Alkem Laboratories Limited has ROE of 17.84%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Alkem Laboratories Limited?

Alkem Laboratories Limited has debt-to-equity of 0.12.

Is Alkem Laboratories Limited a good investment?

Bull Run gives Alkem Laboratories Limited a score of 54/100. This is not investment advice — consult a SEBI-registered advisor.